NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its first-quarter revenues rose 19 percent year over year as reagent and disposable sales increased 22 percent.

The Sunnyvale, Calif.-based firm said that total revenues came in at $91.9 million, up from $77.3 million a year ago, and topping the average analyst estimate of $89.1 million.

Reagent and disposable sales shot up to $75.9 million from $62.1 million a year ago, while system and other sales increased 5 percent to $16.0 million from $15.2 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.